InvestorsHub Logo
Followers 16
Posts 3999
Boards Moderated 0
Alias Born 01/12/2004

Re: None

Friday, 02/10/2017 10:35:13 AM

Friday, February 10, 2017 10:35:13 AM

Post# of 166
Marathon getting $89k for DMD drug. Administration pushing for lower drug prices, so competition in this space would be good in that respect. PTC will be pushing the FDA on this.
Dip seems good for investors. I don't see this as bad news for PTC. Just the opposite. I realize the patients who potentially benefit from Marathon's drug and Ataluren drug are initially different. Interesting that SRPT was up on the news.

http://www.wsj.com/amp/articles/marathon-pharmaceuticals-to-charge-89-000-for-muscular-dystrophy-drug-1486738267

http://wincountry.com/news/articles/2017/feb/09/fda-approves-marathon-pharmaceuticals-dmd-drug/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTCT News